Open-Label Phase 3 Long-Term Safety Study of Migalastat
Status:
Terminated
Trial end date:
2016-02-17
Target enrollment:
Participant gender:
Summary
This was a long-term, open-label study of migalastat (123 milligrams [mg] of migalastat
[equivalent to 150 mg of migalastat hydrochloride]) (migalastat) in participants with Fabry
disease who completed treatment in a previous monotherapy trial with migalastat.